vs

Side-by-side financial comparison of MasterCraft Boat Holdings, Inc. (MCFT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $78.2M, roughly 1.9× MasterCraft Boat Holdings, Inc.). MasterCraft Boat Holdings, Inc. runs the higher net margin — 4.8% vs -5.5%, a 10.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 3.0%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $7.6M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -8.9%).

The MasterCraft Boat Company is an American manufacturer of luxury high-performance boats. The company was founded in 1968 in Maryville, Tennessee, and is currently headquartered in Vonore, Tennessee. MasterCraft boats are used in waterskiing, wakeboarding and wake surfing.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

MCFT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.9× larger
TARS
$151.7M
$78.2M
MCFT
Growing faster (revenue YoY)
TARS
TARS
+125.4% gap
TARS
128.4%
3.0%
MCFT
Higher net margin
MCFT
MCFT
10.3% more per $
MCFT
4.8%
-5.5%
TARS
More free cash flow
TARS
TARS
$5.3M more FCF
TARS
$13.0M
$7.6M
MCFT
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-8.9%
MCFT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
MCFT
MCFT
TARS
TARS
Revenue
$78.2M
$151.7M
Net Profit
$3.7M
$-8.4M
Gross Margin
25.0%
Operating Margin
73.4%
-5.3%
Net Margin
4.8%
-5.5%
Revenue YoY
3.0%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.45
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MCFT
MCFT
TARS
TARS
Q1 26
$78.2M
Q4 25
$71.8M
$151.7M
Q3 25
$69.0M
$118.7M
Q2 25
$79.5M
$102.7M
Q1 25
$76.0M
$78.3M
Q4 24
$63.4M
$66.4M
Q3 24
$65.4M
$48.1M
Q2 24
$94.3M
$40.8M
Net Profit
MCFT
MCFT
TARS
TARS
Q1 26
$3.7M
Q4 25
$2.5M
$-8.4M
Q3 25
$3.6M
$-12.6M
Q2 25
$5.7M
$-20.3M
Q1 25
$3.7M
$-25.1M
Q4 24
$2.7M
$-23.1M
Q3 24
$-5.1M
$-23.4M
Q2 24
$6.2M
$-33.3M
Gross Margin
MCFT
MCFT
TARS
TARS
Q1 26
25.0%
Q4 25
21.6%
Q3 25
22.3%
Q2 25
23.2%
Q1 25
20.8%
Q4 24
17.2%
Q3 24
18.1%
Q2 24
23.8%
Operating Margin
MCFT
MCFT
TARS
TARS
Q1 26
73.4%
Q4 25
3.8%
-5.3%
Q3 25
5.5%
-12.2%
Q2 25
7.5%
-21.6%
Q1 25
5.4%
-33.5%
Q4 24
0.3%
-36.8%
Q3 24
1.5%
-52.3%
Q2 24
11.2%
-81.6%
Net Margin
MCFT
MCFT
TARS
TARS
Q1 26
4.8%
Q4 25
3.5%
-5.5%
Q3 25
5.3%
-10.6%
Q2 25
7.2%
-19.8%
Q1 25
4.9%
-32.1%
Q4 24
4.3%
-34.8%
Q3 24
-7.9%
-48.7%
Q2 24
6.6%
-81.6%
EPS (diluted)
MCFT
MCFT
TARS
TARS
Q1 26
$0.45
Q4 25
$0.16
$-0.17
Q3 25
$0.22
$-0.30
Q2 25
$0.34
$-0.48
Q1 25
$0.23
$-0.64
Q4 24
$0.17
$-0.57
Q3 24
$-0.31
$-0.61
Q2 24
$0.38
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MCFT
MCFT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$84.6M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$189.3M
$343.4M
Total Assets
$277.9M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MCFT
MCFT
TARS
TARS
Q1 26
$84.6M
Q4 25
$81.4M
$417.3M
Q3 25
$67.3M
$401.8M
Q2 25
$79.4M
$381.1M
Q1 25
$66.5M
$407.9M
Q4 24
$62.9M
$291.4M
Q3 24
$14.2M
$317.0M
Q2 24
$86.2M
$323.6M
Total Debt
MCFT
MCFT
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$49.5M
$71.7M
Q2 24
$49.3M
$71.6M
Stockholders' Equity
MCFT
MCFT
TARS
TARS
Q1 26
$189.3M
Q4 25
$189.1M
$343.4M
Q3 25
$185.5M
$335.1M
Q2 25
$183.4M
$332.6M
Q1 25
$182.1M
$342.5M
Q4 24
$178.3M
$224.5M
Q3 24
$175.4M
$237.5M
Q2 24
$183.7M
$252.2M
Total Assets
MCFT
MCFT
TARS
TARS
Q1 26
$277.9M
Q4 25
$259.7M
$562.2M
Q3 25
$259.3M
$534.6M
Q2 25
$259.9M
$495.0M
Q1 25
$261.9M
$500.8M
Q4 24
$250.1M
$377.0M
Q3 24
$309.1M
$376.3M
Q2 24
$259.9M
$376.8M
Debt / Equity
MCFT
MCFT
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.28×
0.30×
Q2 24
0.27×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MCFT
MCFT
TARS
TARS
Operating Cash FlowLast quarter
$13.4M
$19.3M
Free Cash FlowOCF − Capex
$7.6M
$13.0M
FCF MarginFCF / Revenue
9.8%
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
3.58×
TTM Free Cash FlowTrailing 4 quarters
$29.5M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MCFT
MCFT
TARS
TARS
Q1 26
$13.4M
Q4 25
$15.6M
$19.3M
Q3 25
$-6.8M
$18.3M
Q2 25
$20.4M
$-29.4M
Q1 25
$6.3M
$-20.7M
Q4 24
$6.4M
$-22.2M
Q3 24
$2.4M
$-8.7M
Q2 24
$-14.4M
Free Cash Flow
MCFT
MCFT
TARS
TARS
Q1 26
$7.6M
Q4 25
$14.0M
$13.0M
Q3 25
$-9.9M
$16.3M
Q2 25
$17.9M
$-30.4M
Q1 25
$4.3M
$-21.2M
Q4 24
$4.0M
$-22.3M
Q3 24
$199.0K
$-8.9M
Q2 24
$-15.4M
FCF Margin
MCFT
MCFT
TARS
TARS
Q1 26
9.8%
Q4 25
19.5%
8.6%
Q3 25
-14.4%
13.8%
Q2 25
22.5%
-29.6%
Q1 25
5.7%
-27.1%
Q4 24
6.4%
-33.5%
Q3 24
0.3%
-18.6%
Q2 24
-37.8%
Capex Intensity
MCFT
MCFT
TARS
TARS
Q1 26
Q4 25
2.3%
4.2%
Q3 25
4.5%
1.6%
Q2 25
3.3%
1.0%
Q1 25
2.6%
0.8%
Q4 24
3.8%
0.1%
Q3 24
3.4%
0.6%
Q2 24
2.5%
Cash Conversion
MCFT
MCFT
TARS
TARS
Q1 26
3.58×
Q4 25
6.17×
Q3 25
-1.88×
Q2 25
3.59×
Q1 25
1.69×
Q4 24
2.34×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons